News
Altesa BioSciences today announced positive topline results from its Phase 2 placebo-controlled study examining the effects of vapendavir in COPD patients challenged with rhinovirus. In this study, ...
Gilead Sciences (NasdaqGS:GILD) announced positive data regarding Livdelzi for PBC and bulevirtide for chronic HDV, underscoring progress in liver disease treatment. During the last quarter, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback